SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-20-006259
Filing Date
2020-05-11
Accepted
2020-05-11 16:21:26
Documents
64
Period of Report
2020-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q nbrv-20200331x10q.htm 10-Q 1933083
2 EX-31.1 nbrv-20200331ex3115e0c21.htm EX-31.1 12809
3 EX-31.2 nbrv-20200331ex312151e19.htm EX-31.2 12699
4 EX-32.1 nbrv-20200331ex321279176.htm EX-32.1 7451
5 EX-32.2 nbrv-20200331ex322cea0e8.htm EX-32.2 7227
  Complete submission text file 0001558370-20-006259.txt   6623162

Data Files

Seq Description Document Type Size
6 EX-101.INS nbrv-20200331.xml EX-101.INS 1172272
7 EX-101.SCH nbrv-20200331.xsd EX-101.SCH 52373
8 EX-101.CAL nbrv-20200331_cal.xml EX-101.CAL 47110
9 EX-101.DEF nbrv-20200331_def.xml EX-101.DEF 245426
10 EX-101.LAB nbrv-20200331_lab.xml EX-101.LAB 483847
11 EX-101.PRE nbrv-20200331_pre.xml EX-101.PRE 402097
Mailing Address 1000 CONTINENTAL DRIVE SUITE 600 KING OF PRUSSIA PA 19406
Business Address 56 FITZWILLIAM SQUARE DUBLIN L2 2 (610) 816-6640
Nabriva Therapeutics plc (Filer) CIK: 0001641640 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L2 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37558 | Film No.: 20865115
SIC: 2834 Pharmaceutical Preparations